Cediranib(AstraZeneca)은 Non-Small Cell Lung Cancer 표적 ADC로, Non-Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: targets in the VEGF and PI3K pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 15% (ClinicalTrials.gov NCT00227760). 차별점: Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally.
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Recruiting
ADC) targeting HER2, either alone or in combination with the VE
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally
targets in the VEGF and PI3K pathway
DNA damage and consequent sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi), a vulnerability that is being tested in c
biomarkers to target potential treatments
resistance to PARPi might arise in this setting, we modeled PARPi resistance in IDH-mutant tumors via serial transplantation of patie
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Cediranib(AstraZeneca)은 Non-Small Cell Lung Cancer 표적 ADC로, Non-Small Cell Lung Cancer 영역에서 개발·상용화 중입니다. 작용기전: targets in the VEGF and PI3K pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 15% (ClinicalTrials.gov NCT00227760). 차별점: Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally.
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Recruiting
ADC) targeting HER2, either alone or in combination with the VE
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally
targets in the VEGF and PI3K pathway
DNA damage and consequent sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi), a vulnerability that is being tested in c
biomarkers to target potential treatments
resistance to PARPi might arise in this setting, we modeled PARPi resistance in IDH-mutant tumors via serial transplantation of patie
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.